Leucine

Leucine

SCHEMBL2292230

CC(C)C[C@H](N)C(=O)O.NCc1cc2ccccc2oc1=O

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 8/20 0.46
MMP2 P08253 1/20 0.45
MMP9 P14780 1/20 0.45
ADAM17 P78536 1/20 0.45
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.44
CA12 O43570 2/20 0.44
CA9 Q16790 2/20 0.44
CA1 P00915 1/20 0.44
CA3 P07451 1/20 0.44
TSHR P16473 1/20 0.44
CA4 P22748 1/20 0.44
CA6 P23280 1/20 0.44
CA5A P35218 1/20 0.44
CA7 P43166 1/20 0.44
GPR35 Q9HC97 1/20 0.44
CA14 Q9ULX7 1/20 0.44
CA5B Q9Y2D0 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL472753 0.83 MAOB (0.56) MAOBMMP2MMP9ADAM17NPC1
Carbamic Acid SCHEMBL8995121 0.82 MMP2 (0.56) MAOBMMP2MMP9ADAM17NPC1
SCHEMBL5281333 0.81 MMP2 (0.52) MAOBMMP2MMP9ADAM17NPC1
SCHEMBL94133 0.80 POLB (0.59) MAOBMMP2MMP9ADAM17NPC1
SCHEMBL29934196 0.80 POLB (0.59) MAOBMMP2MMP9ADAM17NPC1
SCHEMBL3237487 0.79 POLB (0.58) MAOBMMP2MMP9ADAM17NPC1
Butane SCHEMBL20446706 0.78 MAOB (0.62) MAOBMMP2MMP9ADAM17NPC1
Acetic Acid SCHEMBL2033161 0.78 MAOB (0.50) MAOBMMP2MMP9ADAM17NPC1
Naphthalene SCHEMBL8050416 0.76 SLC7A5 (0.69) SLC7A5
Naphthalene SCHEMBL8050413 0.76 SLC7A5 (0.69) SLC7A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9631219-B2 Metabolic rate indicator for cellular populations NALCO COMPANY (US) 2017-04-25 US disclosed
WO-2011106363-A2 METABOLIC RATE INDICATOR FOR CELLULAR POPULATIONS NALCO COMPANY (US) 2011-09-01 WO disclosed
US-20110207111-A1 METABOLIC RATE INDICATOR FOR CELLULAR POPULATIONS ECOLAB USA INC. 2011-08-25 US disclosed
US-7695930-B2 Method for the detection, identification and/or quantification of microoganisms with peptidase activity using phenoxazinone derivatives as enzyme substrates BIOMERIEUX (FR) 2010-04-13 US disclosed
US-20080286820-A1 Novel phenoxazinone derivatives as enzyme substrates and use thereof as indicator in the detection of microorganisms with peptidase activity BIOMERIEUX (FR) 2008-11-20 US disclosed
US-7420054-B2 Phenoxazinone derivatives as enzyme substrates and use thereof as indicator in the detection of microorganisms with peptidase activity BIOMERIEUX (FR) 2008-09-02 US disclosed
EP-1625117-B1 NOVEL PHENOXAZINONE DERIVATIVES AS ENZYME SUBSTRATES AND USE THEREOF AS INDICTOR IN THE DETECTION OF MICROORGANISMS WITH PEPTIDASE ACTIVITY BIOMERIEUX SA (FR) 2008-01-09 EP disclosed
US-20060121551-A1 Novel phenoxazinone derivatives as enzyme substrates and use thereof as indicator in the detection of microorganisms with peptidase activity BIOMERIEUX (FR) 2006-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060121551-A1 Novel phenoxazinone derivatives as enzyme substrates and use thereof as indicator in the detection of microorganisms with peptidase activity PEPD, CTRL, PM20D2 MAOB 85/4885MMP2 54/4885MMP9 414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.